Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Q4 2024 Neurocrine Biosciences Inc Earnings Call
Good day, everyone, and welcome to today's Neurocrine Biosciences reports Q4 and fiscal year 2024 Earnings Call. (Operator Instructions) Please note today's call will be recorded and I will be standing by should you need any assistance.
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock a buy.
Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer
Neurocrine Biosciences Inc Q4 Profit Decreases, Misses Estimates
Neurocrine Biosciences Inc (NBIX) reported earnings for fourth quarter that decreased from the same period last year and missed the
These Stocks Are Moving the Most Today: Amazon, Affirm, Pinterest, Take-Two, Bill Holdings, e.l.f. Beauty, Neurocrine Biosciences, and More
Amazon falls after guidance disappoints and cloud-computing growth misses estimates, Affirm jumps after fiscal second-quarter ...
Neurocrine price target lowered to $185 from $190 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...
American Association of Individual Investors19h
Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Investing52m
Neurocrine Biosciences stock falls on revenue miss
Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® ...
Neurocrine price target lowered to $179 from $184 at BofA
BofA lowered the firm’s price target on Neurocrine (NBIX) to $179 from $184 and keeps a Buy rating on the shares after the company reported Q4 ...
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tokio Marine Asset Management Co. Ltd.
Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...